一线治疗后急性白血病(前)青春期男孩冷冻睾丸组织中微小残留病的检测
该初步研究分析14例(前)青春期急性淋巴细胞白血病或急性髓细胞白血病男孩一线化疗后、造血干细胞移植前冷冻的睾丸组织,用RT-qPCR和qPCR检测致癌融合基因或Ig/TCR克隆性重排,36%(5/14)样本检出微小残留病,分子检测与传统组织病理学不一致率为21%,分子法敏感性更高。
要点
- 分子生物学技术可在冷冻睾丸组织中检出微小残留病,检出率为36%(5/14)。
- 分子检测与传统组织病理学不一致率为21%,分子法敏感性更高。
- 临床或组织学特征与睾丸组织微小残留病状态无显著关联。
核心结论
- 该初步研究证明在冷冻睾丸组织中检测微小残留病可行,可指导选择最安全的生育力恢复技术。
研究设计与样本
- 初步研究,分析14例(前)青春期急性淋巴细胞白血病或急性髓细胞白血病男孩一线化疗后、造血干细胞移植前冷冻的睾丸组织。
主要发现
- 分子生物学技术检出36%(5/14)的睾丸组织样本存在微小残留病。
- 传统组织病理学与分子检测不一致率为21%,分子法敏感性更高。
- 临床或组织学特征与睾丸组织微小残留病状态无显著关联。
关键数值与推荐
- 采用RT-qPCR和qPCR检测致癌融合基因或免疫球蛋白基因/T细胞受体(Ig/TCR)克隆性重排。
临床怎么用
- 作者认为在冷冻睾丸组织中检测微小残留病可帮助指导选择最安全的生育力恢复策略,以尽量减少重新引入恶性细胞的风险。
- 作者认为该方法强调在急性白血病完全缓解后冷冻睾丸组织的重要性。
局限性
- 本研究为初步研究,急性淋巴细胞白血病或急性髓细胞白血病患者的睾丸组织样本量小,可能限制研究结果的普遍性。
- 需要更大队列的进一步研究来验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is it feasible to detect minimal residual disease (MRD) in cryopreserved testicular tissue (TT) from (pre)pubertal boys diagnosed with acute leukemia using molecular biology techniques? SUMMARY ANSWER: This pilot study demonstrates the feasibility of detecting MRD in cryopreserved TT, which could guide the choice of the safest techniques for fertility restoration. WHAT IS KNOWN ALREADY: Fertility preservation through testicular tissue freezing (TTF) is offered to (pre)pubertal boys undergoing highly gonadotoxic treatment. However, the risk of reintroducing leukemic cells during fertility restoration has not been adequately addressed. To date, no study has evaluated the feasibility of detecting residual disease using molecular biology within cryopreserved, thawed and unfixed TT. STUDY DESIGN, SIZE, DURATION: This pilot study analyzed cryopreserved TT from 14 (pre)pubertal boys diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML) who had already received first-line chemotherapy and underwent TTF before hematopoietic stem cell transplantation. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study included cryopreserved TT from 14 (pre)pubertal boys. Molecular biology techniques, including RT-qPCR and qPCR, were used to detect oncogenic fusion genes or clonal rearrangements of immunoglobulin genes or T-cell receptor (Ig/TCR) in cryopreserved TT samples. MAIN RESULTS AND THE ROLE OF CHANCE: MRD was identified in 36% (5 out of 14) of TT samples using molecular biology techniques. A 21% discordance was observed between conventional histopathology and molecular detection, with molecular methods showing higher sensitivity. No significant association was found between clinical or histological characteristics and MRD status in the TT. LIMITATIONS, REASONS FOR CAUTION: This study is a pilot study with a small sample size of TT samples from patients with ALL or AML, which may limit the generalizability of the findings. Further studies with larger cohorts are needed to validate our data. WIDER IMPLICATIONS OF THE FINDINGS: The detection of MRD in cryopreserved TT using molecular biology techniques could help guide the selection of the safest fertility restoration strategies for leukemic patients by minimizing the risk of reintroducing malignant cells. This approach underscores the importance of cryopreserving TT after complete remission of acute leukemia (AL). STUDY FUNDING/COMPETING INTEREST(S): The study was funded by Rouen University Hospital, GIRCI NO, French Biomedicine Agency, and Ligue National Contre le Cancer. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Feraille A, Etancelin P, Troche S, et al. Detection of minimal residual disease in cryopreserved testicular tissue from (pre)pubertal boys with acute leukemia following first-line therapy. Hum Reprod. 2025. PMID: 40389239. doi:10.1093/humrep/deaf093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。